ClinicalTrials.Veeva

Menu
D

Derm Effects | London, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

PF-04965842
ESK-001

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 3 total trials

A Study of Barzolvolimab in Patients With Prurigo Nodularis

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Enrolling
Prurigo Nodularis
Other: Matching Placebo
Biological: barzolvolimab

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

A
Celldex Therapeutics logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems